|

SHR-1316 Injection Clinical Trials

5 actively recruiting trials

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.2
  • Shanghai Hengrui Pharmaceutical Co., Ltd.2
  • Shanghai Shengdi Pharmaceutical Co., Ltd1

Indications

  • Cancer5
  • Advanced Cervical Cancer1
  • PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer1
  • Widespread Small Cell Lung Cancer1
  • Malignant Solid Tumors1

Other5 trials

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Phase 3
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Phase 1/2
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Phase 2
Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.